Physician profile
Chaim Charytan
NPI 1992723738
$33,507.88
in general payments reported to CMS, 2019-2025
25 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $25K · 2020: $789 · 2021: $7,034 · 2022: $807 · 2023: $228 · 2024: $147.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $313 · Education: $61.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $312.88 |
| Education | $61.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $13,007.29 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $11,322.23 | 2019-2023 | Farxiga |
| Pharmacosmos Therapeutics INC. | $6,561.79 | 2021 | |
| C. R. Bard, INC. & Subsidiaries | $533.33 | 2020 | |
| Vifor Pharma, INC. | $488.44 | 2019-2024 | Veltassa, Korsuva |
| Amgen INC. | $204.76 | 2019-2024 | Tavneos |
| Otsuka America Pharmaceutical, INC. | $204.73 | 2019-2024 | Jynarque |
| Opko Pharmaceuticals, LLC | $191.59 | 2019-2022 | |
| Fresenius USA Marketing, INC. | $150.23 | 2019-2023 | Velphoro |
| Aurinia Pharma U.S., INC. | $114.03 | 2021-2023 | Lupkynis |
| Travere Therapeutics, INC. | $107.65 | 2019-2023 | |
| Alexion Pharmaceuticals, INC. | $92.29 | 2019-2023 | Ultomiris |
| Bayer Healthcare Pharmaceuticals INC. | $89.62 | 2022 | |
| Pfizer INC. | $85.65 | 2019 | |
| Mallinckrodt Hospital Products INC. | $84.55 | 2022-2023 | Acthar |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Calliditas Therapeutics US INC. | $62.99 | 2022 | |
| Janssen Pharmaceuticals, INC | $50.84 | 2019-2020 | |
| Horizon Therapeutics Plc | $41.41 | 2021-2022 | |
| Cumberland Pharmaceuticals, INC. | $33.77 | 2019 | |
| Alnylam Pharmaceuticals INC. | $28.85 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $26.84 | 2024 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $25.00 | 2020 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chaim Charytan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.